Dendreon to Host Conference Call on August 8 to Announce Second Quarter Financial Results


Dendreon to Host Conference Call on August 8 to Announce Second Quarter Financial Results

-- Company Announces Webcast Presentations at Upcoming Conference --

SEATTLE--(BUSINESS WIRE)-- July 15, 2013-- Dendreon Corporation (NAS: DNDN) today announced that management will host a conference call on Thursday, August 8, 2013, at 4:30 p.m. EDT to review second quarter financial results.

Access to the discussion may be obtained as follows:


4:30 p.m. EDT / 1:30 p.m. PDT


August 8, 2013


1-877-548-9590 (domestic) or +1-720-545-0037 (international);

conference pass code: 18807239

Webcast: (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 18807239. The replay will be available from 7:30 p.m. EDT on Thursday, August 8, until 11:59 p.m. EDT on Wednesday, August 14. In addition, the webcast will be archived for on-demand listening for 90 days at

Dendreon Corporation also announced that management will present at the following conference:

  • Canaccord Genuity 33rd Annual Growth Conference in Boston, MA, on August 14 at 9:00 a.m. EDT

The presentation will be audio webcast live and available for replay from Dendreon's website, If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit

Dendreon Corporation
Corporate Communications
Lindsay Rocco, 862-596-1304
Investor Relations
Nicole Soley, 206-455-2220

KEYWORDS: United States North America Massachusetts Washington


The article Dendreon to Host Conference Call on August 8 to Announce Second Quarter Financial Results originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published